Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk o...
Uloženo v:
| Vydáno v: | Journal of gastroenterology Ročník 56; číslo 11; s. 951 - 963 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Singapore
Springer Singapore
01.11.2021
Springer Springer Nature B.V |
| Témata: | |
| ISSN: | 0944-1174, 1435-5922, 1435-5922 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan. |
|---|---|
| AbstractList | Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan. Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan.Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan. |
| Audience | Academic |
| Author | Eguchi, Yuichiro Kamada, Yoshihiro Yoneda, Masashi Enomoto, Nobuyuki Ono, Masafumi Akuta, Norio Iwasa, Motoh Ikejima, Kenichi Miwa, Hiroto Shimosegawa, Tooru Kogiso, Tomomi Koike, Kazuhiko Otsuka, Motoyuki Tamaki, Nobuharu Chayama, Kazuaki Tokushige, Katsutoshi Itoh, Yoshito Yoneda, Masato Takehara, Tetsuo |
| Author_xml | – sequence: 1 givenname: Katsutoshi surname: Tokushige fullname: Tokushige, Katsutoshi email: tokushige.katsutoshi@twmu.ac.jp organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women’s Medical University – sequence: 2 givenname: Kenichi surname: Ikejima fullname: Ikejima, Kenichi organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 3 givenname: Masafumi surname: Ono fullname: Ono, Masafumi organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 4 givenname: Yuichiro surname: Eguchi fullname: Eguchi, Yuichiro organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 5 givenname: Yoshihiro surname: Kamada fullname: Kamada, Yoshihiro organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 6 givenname: Yoshito surname: Itoh fullname: Itoh, Yoshito organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 7 givenname: Norio surname: Akuta fullname: Akuta, Norio organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 8 givenname: Masato surname: Yoneda fullname: Yoneda, Masato organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 9 givenname: Motoh surname: Iwasa fullname: Iwasa, Motoh organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 10 givenname: Masashi surname: Yoneda fullname: Yoneda, Masashi organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 11 givenname: Motoyuki surname: Otsuka fullname: Otsuka, Motoyuki organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 12 givenname: Nobuharu surname: Tamaki fullname: Tamaki, Nobuharu organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 13 givenname: Tomomi surname: Kogiso fullname: Kogiso, Tomomi organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 14 givenname: Hiroto surname: Miwa fullname: Miwa, Hiroto organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 15 givenname: Kazuaki surname: Chayama fullname: Chayama, Kazuaki organization: The Japan Society of Hepatology – sequence: 16 givenname: Nobuyuki surname: Enomoto fullname: Enomoto, Nobuyuki organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 17 givenname: Tooru surname: Shimosegawa fullname: Shimosegawa, Tooru organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology – sequence: 18 givenname: Tetsuo surname: Takehara fullname: Takehara, Tetsuo organization: The Japan Society of Hepatology – sequence: 19 givenname: Kazuhiko surname: Koike fullname: Koike, Kazuhiko organization: Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34533632$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktr3DAUhUVJaSZp_0AXxdBNN06uXra8KYSQPiDQTbsWsnw9o6CxppI8JP8-mk6adEIJWgiuvnOke3VOyNEUJiTkPYUzCtCeJwDJZQ2M1kDbrqlvX5EFFaUkO8aOyAI6IWpKW3FMTlK6AaAcpHpDjrmQnDecLUi82roBJ4t1bxIOlfVuctb4ahONzc5itZwLUKqYqjHEqrzBeBtWwTtbjSbnu8q7LcZqcAmLxfkBkDKaHFa4MdlllyoGDN6S16PxCd897Kfk15ern5ff6usfX79fXlzXVjYy14yLnvc4KlSjZGOrgGHbKOwobZhsWN8MUFpAxqViDBTlrB-7obO9ZdLwlp-Sz3vfzdyvcbA45Wi83kS3NvFOB-P04cnkVnoZtlpJTqFhxeDTg0EMv2dMWa9dsui9mTDMSTPZCt6BYLygH5-hN2GOZRA7SonyNsXhiVoaj9pNYyj32p2pvmipKH0o2FFn_6HKGnDtbInA6Er9QPDh30YfO_z7ywVge8DGkFLE8RGhoHdR0vso6RIl_SdK-raI1DORdbl8Y9gNy_mXpXwvTeWeaYnxaRovqO4B7lTddA |
| CitedBy_id | crossref_primary_10_1007_s12328_025_02192_1 crossref_primary_10_1016_j_ultrasmedbio_2023_03_023 crossref_primary_10_3390_molecules29081859 crossref_primary_10_31083_j_fbl2812360 crossref_primary_10_3390_nu14153163 crossref_primary_10_3390_biomedicines9121853 crossref_primary_10_3748_wjg_v29_i23_3703 crossref_primary_10_1097_MOP_0000000000001138 crossref_primary_10_3350_cmh_2023_0315 crossref_primary_10_7717_peerj_17094 crossref_primary_10_1038_s41440_024_02028_4 crossref_primary_10_3390_diagnostics11122316 crossref_primary_10_1002_mco2_226 crossref_primary_10_1007_s00535_023_02047_x crossref_primary_10_1097_MEG_0000000000002588 crossref_primary_10_1111_1346_8138_17752 crossref_primary_10_1007_s00535_022_01932_1 crossref_primary_10_1007_s10067_025_07364_5 crossref_primary_10_1038_s43856_024_00499_7 crossref_primary_10_1186_s12876_024_03386_6 crossref_primary_10_1111_hepr_13764 crossref_primary_10_1038_s41598_023_39641_1 crossref_primary_10_1002_hep4_1993 crossref_primary_10_1016_j_gastha_2025_100668 crossref_primary_10_3350_cmh_2024_0214 crossref_primary_10_3390_diagnostics13030503 crossref_primary_10_1136_bmjopen_2023_080549 crossref_primary_10_1111_apt_18205 crossref_primary_10_3389_fcell_2024_1482838 crossref_primary_10_1002_jgh3_13019 crossref_primary_10_1080_14656566_2025_2486354 crossref_primary_10_1111_jgh_15787 crossref_primary_10_1080_00365521_2022_2148835 crossref_primary_10_1097_MD_0000000000037281 crossref_primary_10_1186_s41824_023_00173_6 crossref_primary_10_3390_diagnostics14131317 crossref_primary_10_1111_jdi_70032 crossref_primary_10_3389_fphar_2024_1423903 crossref_primary_10_3390_diagnostics14111083 crossref_primary_10_1097_MD_0000000000032357 crossref_primary_10_1371_journal_pone_0330504 crossref_primary_10_3389_fphar_2023_1286449 crossref_primary_10_1111_hepr_13757 crossref_primary_10_1186_s41043_024_00618_z crossref_primary_10_1016_j_gastha_2024_100611 crossref_primary_10_1371_journal_pone_0315752 crossref_primary_10_1038_s41440_023_01179_0 crossref_primary_10_3389_fendo_2024_1362396 crossref_primary_10_2169_internalmedicine_4820_24 crossref_primary_10_1111_jgh_16222 crossref_primary_10_1265_ehpm_25_00025 crossref_primary_10_3390_biom13081264 crossref_primary_10_1002_joa3_13045 crossref_primary_10_3350_cmh_2022_0336 crossref_primary_10_1096_fj_202101975R crossref_primary_10_3389_fendo_2023_1156381 crossref_primary_10_1016_j_jaad_2024_03_041 crossref_primary_10_1097_HEP_0000000000001058 crossref_primary_10_1007_s00535_024_02122_x crossref_primary_10_3389_fendo_2023_1111430 crossref_primary_10_1007_s12072_022_10453_1 crossref_primary_10_1016_j_jceh_2023_01_016 crossref_primary_10_1002_fsn3_4331 crossref_primary_10_1253_circj_CJ_25_0169 crossref_primary_10_1186_s13098_022_00887_w crossref_primary_10_1111_jgh_15766 crossref_primary_10_1007_s00535_023_02038_y crossref_primary_10_1186_s12944_025_02588_5 crossref_primary_10_1007_s00535_021_01833_9 crossref_primary_10_4254_wjh_v15_i5_641 crossref_primary_10_3390_antiox13070766 crossref_primary_10_7759_cureus_83712 crossref_primary_10_1016_j_jep_2024_119199 crossref_primary_10_3389_fnut_2023_1121203 crossref_primary_10_3390_ijms26031043 crossref_primary_10_3390_nu15051269 crossref_primary_10_1007_s00535_024_02179_8 crossref_primary_10_1111_liv_15678 crossref_primary_10_1038_s41598_022_21039_0 crossref_primary_10_2147_DMSO_S447897 crossref_primary_10_3390_nu14010103 crossref_primary_10_1002_jgh3_13110 crossref_primary_10_1111_liv_16124 crossref_primary_10_1016_j_cld_2023_01_022 crossref_primary_10_3389_fphar_2022_908128 crossref_primary_10_1002_jgh3_12898 crossref_primary_10_3390_nu15143248 crossref_primary_10_1210_clinem_dgae621 crossref_primary_10_1016_j_jstrokecerebrovasdis_2023_107537 crossref_primary_10_3350_cmh_2022_0357 crossref_primary_10_3390_nu15061360 crossref_primary_10_3390_life13112144 crossref_primary_10_1039_D3FO05111K crossref_primary_10_3390_diagnostics15081023 crossref_primary_10_1007_s12664_022_01314_8 crossref_primary_10_1186_s12902_024_01690_6 crossref_primary_10_1002_jgh3_70277 crossref_primary_10_1159_000536211 crossref_primary_10_3390_jcm12134468 crossref_primary_10_3390_jcm12206561 crossref_primary_10_1002_jgh3_13067 crossref_primary_10_1016_j_peptides_2023_171146 crossref_primary_10_1002_jgh3_13057 crossref_primary_10_1111_jdi_13812 crossref_primary_10_1016_j_obpill_2024_100142 crossref_primary_10_2169_internalmedicine_5250_25 crossref_primary_10_3389_fmicb_2025_1576221 crossref_primary_10_12998_wjcc_v10_i28_10293 crossref_primary_10_3389_fmed_2023_1073025 crossref_primary_10_3390_nu16223847 crossref_primary_10_1007_s12072_024_10698_y crossref_primary_10_1007_s11102_025_01500_9 crossref_primary_10_1016_j_lfs_2025_123395 crossref_primary_10_1111_jgh_16315 crossref_primary_10_1111_jgh_16552 crossref_primary_10_3892_mco_2023_2676 crossref_primary_10_1007_s00535_024_02093_z crossref_primary_10_1016_j_clinsp_2024_100387 crossref_primary_10_1186_s12876_023_02848_7 crossref_primary_10_1177_03000605231204462 crossref_primary_10_1007_s12072_022_10387_8 crossref_primary_10_1007_s12328_023_01760_7 crossref_primary_10_1038_s41598_024_52797_8 crossref_primary_10_1002_jgh3_13012 crossref_primary_10_1016_j_lfs_2025_123638 crossref_primary_10_1038_s41598_025_86424_x crossref_primary_10_3390_jcm13041158 crossref_primary_10_1016_j_jnutbio_2023_109353 crossref_primary_10_3390_diagnostics14070725 crossref_primary_10_1007_s00535_023_02002_w crossref_primary_10_1038_s41598_023_34942_x crossref_primary_10_1111_jgh_16144 crossref_primary_10_1186_s12906_024_04692_y crossref_primary_10_1186_s41043_024_00714_0 crossref_primary_10_3389_fnagi_2022_985109 crossref_primary_10_3389_fmed_2025_1542741 crossref_primary_10_1111_1346_8138_17277 crossref_primary_10_3390_nu15183878 crossref_primary_10_2169_internalmedicine_4128_24 crossref_primary_10_3999_jscpt_56_3_142 crossref_primary_10_1111_hepr_13943 crossref_primary_10_3389_fendo_2023_1171397 crossref_primary_10_3390_healthcare13090969 crossref_primary_10_3390_nu15224724 crossref_primary_10_1111_jvh_13805 crossref_primary_10_2147_DMSO_S426102 crossref_primary_10_1002_hep4_1971 crossref_primary_10_1097_MEG_0000000000002471 crossref_primary_10_1038_s41598_024_73739_4 crossref_primary_10_1111_liv_15792 crossref_primary_10_1111_jdi_14246 crossref_primary_10_4252_wjsc_v17_i5_99638 crossref_primary_10_1016_j_aohep_2022_100670 crossref_primary_10_1097_MEG_0000000000002754 crossref_primary_10_3390_nu14173453 crossref_primary_10_1080_00365521_2022_2123252 crossref_primary_10_1038_s41598_022_16688_0 crossref_primary_10_1136_bmjopen_2023_074851 crossref_primary_10_1007_s00535_025_02242_y |
| Cites_doi | 10.1007/s00535-017-1364-8 10.1016/j.jhep.2018.05.036 10.1002/hep.29273 10.1371/journal.pone.0038322 10.1002/hep.29724 10.1111/hepr.13425 10.1038/ng.2901 10.1002/hep.27490 10.1002/hep.20092 10.3748/wjg.v18.i13.1508 10.1053/j.gastro.2016.06.001 10.1053/j.gastro.2015.04.043 10.1016/j.jhep.2014.11.034 10.1016/j.jhep.2017.05.016 10.1002/edm2.163 10.12688/f1000research.12417.1 10.1111/apt.13816 10.2337/dc10-0856 10.1038/ng.257 10.1053/j.gastro.2015.04.005 10.1002/hep.23823 10.1002/hep.23129 10.1002/hep.22399 10.1111/j.1440-1746.2007.05001.x 10.1002/hep.28394 10.1111/jgh.14448 10.1111/liv.12611 10.1038/nrgastro.2017.109 10.1002/hep.28431 10.1016/j.diabet.2018.08.001 10.1038/oby.2009.274 10.1016/j.jhep.2015.05.006 10.1002/hep.28356 10.1007/s12072-014-9605-x 10.1016/S0140-6736(14)61933-4 10.1016/j.cmet.2017.04.001 10.1038/ajg.2011.327 10.1038/s41598-017-04991-0 10.1186/1471-230X-12-2 10.1007/s00535-011-0436-4 10.1016/j.cgh.2014.04.038 10.2337/dc12-1235 10.1016/j.jhep.2016.05.013 10.1053/j.gastro.2015.11.048 10.1161/JAHA.119.013389 10.1053/j.gastro.2014.11.039 10.1371/journal.pone.0076161 10.1002/hep4.1019 10.1097/MD.0000000000004529 10.1002/hep.23623 10.1038/s41598-020-57935-6 10.1053/j.gastro.2019.12.053 10.1038/ajg.2016.453 10.2169/internalmedicine.4398-19 10.1002/hep.29246 10.1016/j.jhep.2016.04.021 10.1001/jama.2020.2298 10.1007/s00125-011-2446-4 10.1002/hep.29367 10.1016/j.freeradbiomed.2011.10.003 10.1016/S0140-6736(15)00803-X 10.1016/j.atherosclerosis.2016.02.029 10.1111/hepr.12351 10.1002/hep.23276 10.1016/S1542-3565(04)00457-4 10.1111/j.1872-034X.2011.00849.x 10.1016/j.jhep.2013.02.012 10.1111/j.1478-3231.2011.02462.x 10.1056/NEJMoa0907929 10.1053/j.gastro.2018.12.036 10.1053/j.gastro.2020.01.052 10.1038/nature04634 10.1016/j.jhep.2015.08.038 10.1007/s00535-012-0533-z 10.1016/j.jhep.2011.06.010 10.1002/hep.29514 10.1053/j.gastro.2016.01.032 10.1002/hep.21346 10.1111/j.1365-2036.2011.04724.x 10.1097/MEG.0000000000000776 10.1016/j.jhep.2016.04.005 10.1053/j.gastro.2005.03.084 10.1002/hep.29085 10.1111/jgh.12239 10.3748/wjg.v21.i25.7860 10.1002/hep.31622 10.1016/j.bbalip.2013.12.006 10.1002/hep.25756 10.1111/hepr.12840 10.1002/hep.29302 10.1002/hep.23527 10.1001/jamainternmed.2016.9607 10.1002/hep.24558 10.1002/hep.23727 10.1053/j.gastro.2016.01.038 10.1007/s00535-015-1050-7 10.1016/j.jhep.2016.08.019 10.1002/hep.29477 10.1016/S0140-6736(18)32165-2 10.1038/nature10809 10.1007/s00535-018-1474-y 10.1074/jbc.M109.064501 10.1016/j.cgh.2013.04.039 10.1007/s00535-010-0311-8 10.1002/hep.27544 10.1371/journal.pone.0185490 10.1136/gut.2007.126417 10.1111/jgh.14989 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 2021. The Author(s). COPYRIGHT 2021 Springer The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 Springer – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7T5 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU FYUFA GHDGH H94 K9- K9. KB0 M0R M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s00535-021-01796-x |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Immunology Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef ProQuest One Academic Middle East (New) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1435-5922 |
| EndPage | 963 |
| ExternalDocumentID | PMC8531062 A714582800 34533632 10_1007_s00535_021_01796_x |
| Genre | Journal Article Review |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29K 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BKNYI BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP D-I DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IHR IJ- IKXTQ IMOTQ INH IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K9- KDC KOV KOW KPH LAS LLZTM M0R M1P M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PCD PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW X7M YLTOR Z45 Z7U Z7W Z82 Z83 Z87 Z8O Z8Q Z8V Z8W Z91 ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7T5 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c565t-234b3bef8e8f52f7802e768e91162562b6d0632e23582208132bf9d9cbc25a373 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 216 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000696755500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0944-1174 1435-5922 |
| IngestDate | Tue Nov 04 02:00:36 EST 2025 Thu Sep 04 18:23:09 EDT 2025 Wed Nov 05 15:24:58 EST 2025 Sat Nov 29 13:42:29 EST 2025 Sat Nov 29 09:50:05 EST 2025 Thu Apr 03 07:02:00 EDT 2025 Sat Nov 29 06:47:08 EST 2025 Tue Nov 18 22:32:06 EST 2025 Fri Feb 21 02:47:26 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | HCC Cardiovascular disease Treatment NAFLD/NASH guidelines Fibrosis |
| Language | English |
| License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c565t-234b3bef8e8f52f7802e768e91162562b6d0632e23582208132bf9d9cbc25a373 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1007/s00535-021-01796-x |
| PMID | 34533632 |
| PQID | 2584132830 |
| PQPubID | 33411 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8531062 proquest_miscellaneous_2574390423 proquest_journals_2584132830 gale_infotracmisc_A714582800 gale_infotracacademiconefile_A714582800 pubmed_primary_34533632 crossref_primary_10_1007_s00535_021_01796_x crossref_citationtrail_10_1007_s00535_021_01796_x springer_journals_10_1007_s00535_021_01796_x |
| PublicationCentury | 2000 |
| PublicationDate | 2021-11-01 |
| PublicationDateYYYYMMDD | 2021-11-01 |
| PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Singapore |
| PublicationPlace_xml | – name: Singapore – name: Japan – name: Tokyo |
| PublicationTitle | Journal of gastroenterology |
| PublicationTitleAbbrev | J Gastroenterol |
| PublicationTitleAlternate | J Gastroenterol |
| PublicationYear | 2021 |
| Publisher | Springer Singapore Springer Springer Nature B.V |
| Publisher_xml | – name: Springer Singapore – name: Springer – name: Springer Nature B.V |
| References | Kawaguchi, Sumida, Umemura (CR34) 2012; 7 Kawamura, Ikeda, Arase (CR53) 2015; 9 Chitturi, Farrell, Hashimoto (CR25) 2007; 22 Wijarnpreecha, Thongprayoon, Ungprasert (CR68) 2017; 29 Torres, Jones, Shaw, Williams, Ward, Harrison (CR91) 2011; 54 Loomba, Lim, Patton, El-Serag (CR14) 2020; 158 Promrat, Kleiner, Niemeier (CR62) 2010; 51 Musso, Gambino, Cassader, Pagano (CR96) 2010; 52 Sheka, Adeyi, Thompson, Hameed, Crawford, Ikramuddin (CR24) 2020; 323 Ratziu, Charlotte, Heurtier (CR48) 2005; 128 Sinn, Cho, Gu (CR19) 2016; 151 Musso, Cassader, Paschetta, Gambino (CR76) 2017; 177 Ishibashi, Yamashita, Arai (CR104) 2016; 249 Musso, Cassader, Rosina, Gambino (CR64) 2012; 55 Bravi, Bosetti, Tavani, Gallus, La Vecchia (CR69) 2013; 11 Ascha, Hanouneh, Lopez, Tamimi, Feldstein, Zein (CR16) 2010; 51 Chalasani, Younossi, Lavine (CR9) 2018; 67 van der Heijden, Wang, Chu (CR71) 2010; 18 Hamaguchi, Takeda, Kojima (CR26) 2012; 18 Kawamura, Arase, Ikeda (CR15) 2012; 107 Kawakubo, Tanaka, Ochi (CR82) 2020; 10 Oh, Shida, Yamagishi (CR72) 2015; 61 Wong, Aguilar, Cheung (CR2) 2015; 148 Hashiba, Ono, Hyogo (CR7) 2013; 8 Ito, Ishigami, Ishizu (CR51) 2019; 34 Sanyal, Chalasani, Kowdley (CR74) 2010; 362 Johnson, Sachinwalla, Walton (CR70) 2009; 50 Dulai, Singh, Patel (CR11) 2017; 65 Dongiovanni, Petta, Maglio (CR41) 2015; 61 Imajo, Kessoku, Honda (CR59) 2016; 150 Neuschwander-Tetri, Loomba, Sanyal (CR97) 2015; 385 Yoneda, Fujii, Sumida (CR50) 2011; 46 Loomba, Lawitz, Mantry (CR100) 2018; 67 (CR5) 2016; 64 Estes, Anstee, Arias-Loste (CR3) 2018; 69 Mancina, Dongiovanni, Petta (CR42) 2016; 05 Ryan, Itsiopoulos, Thodis (CR66) 2013; 59 Yoneda, Fujita, Inamori (CR58) 2007; 56 He, McPhaul, Li (CR35) 2010; 285 Dongiovanni, Petta, Mannisto (CR89) 2015; 63 Younossi, Anstee, Marietti (CR22) 2018; 15 Kozlitina, Smagris, Stender (CR40) 2014; 46 Sawangjit, Chongmelaxme, Phisalprapa (CR75) 2016; 95 Romero-Gómez, Zelber-Sagi, Trenell (CR67) 2017; 67 Loomba, Noureddin, Kowdley (CR107) 2020; 73 Valenti, Alisi, Galmozzi (CR33) 2010; 52 Ochi, Hirooka, Koizumi (CR56) 2012; 56 Sanyal, Mofrad, Contos (CR73) 2004; 2 Hashimoto, Tokushige (CR28) 2011; 46 Francque, van der Graaff, Kwanten (CR18) 2016; 65 Svegliati-Baroni, Saccomanno, Rychlicki (CR77) 2011; 31 Wong, Adams (CR102) 2019; 392 Pingitore, Pirazzi, Mancina (CR36) 2014; 1841 Kawaguchi, Shima, Mizuno (CR39) 2018; 13 Cui, Philo, Nguyen (CR81) 2016; 65 Lam, Chandramouli, Ahooja, Verma (CR86) 2019; 8 Ratziu, Harrison, Francque (CR98) 2016; 150 Eguchi, Kitajima, Hyogo (CR80) 2015; 45 Lazo, Solga, Horska (CR63) 2010; 33 Eguchi, Hyogo, Ono (CR6) 2012; 47 Lv, Dong, Hu, Lu, Zhou, Qin (CR87) 2020; 3 Younossi, Koenig, Abdelatif, Fazel, Henry, Wymer (CR1) 2016; 64 Donati, Dongiovanni, Romeo (CR43) 2017; 7 Vilar-Gomez, Martinez-Perez, Calzadilla-Bertot (CR65) 2015; 149 Merriman, Ferrell, Patti (CR49) 2006; 44 Houstis, Rosen, Lander (CR29) 2006; 440 Thoma, Day, Trenell (CR61) 2012; 56 Kargiotis, Athyros, Giouleme (CR90) 2015; 21 Ishiba, Sumida, Tanaka (CR55) 2018; 53 Summart, Thinkhamrop, Chamadol, Khuntikeo, Songthamwat, Kim (CR21) 2017; 6 Younossi, Loomba, Rinella (CR99) 2018; 68 Targher, Byrne, Lonardo, Zoppini, Barbui (CR20) 2016; 65 McPherson, Hardy, Dufour (CR54) 2017; 112 Henao-Mejia, Elinav, Jin (CR46) 2012; 482 Friedman, Ratziu, Harrison (CR101) 2018; 67 Sumida, Okanoue, Nakajima (CR108) 2019; 49 Armstrong, Hull, Guo (CR79) 2016; 64 Goh, Pagadala, Dasarathy (CR92) 2015; 35 Akuta, Watanabe, Kawamura (CR88) 2017; 1 Angulo, Kleiner, Dam-Larsen (CR10) 2015; 149 CR12 Loomba, Seguritan, Li (CR45) 2017; 25 Kodama, Tojjar, Yamada, Toda, Patel, Butte (CR109) 2013; 36 Romeo, Kozlitina, Xing (CR32) 2008; 40 Akuta, Kawamura, Fujiyama (CR85) 2020; 59 Boursier, Mueller, Barret (CR44) 2016; 63 Seko, Sumida, Sasaki (CR83) 2018; 53 Lindor, Kowdley, Heathcote (CR94) 2004; 39 Safadi, Konikoff, Mahamid (CR103) 2014; 12 Seko, Sumida, Tanaka (CR38) 2017; 47 McPherson, Hardy, Henderson, Burt, Day, Anstee (CR8) 2015; 62 Maher, Leon, Ryan (CR30) 2008; 48 Bajaj, Brown, Bhullar, Sohi, Kalra, Aronson (CR84) 2018; 44 Leuschner, Lindenthal, Herrmann (CR95) 2010; 52 Vernon, Baranova, Younossi (CR27) 2011; 34 Cotter, Rinella (CR23) 2020; 158 Armstrong, Gaunt, Aithal (CR78) 2016; 387 Castera, Friedrich-Rust, Loomba (CR13) 2019; 156 Xiao, Zhu, Xiao, Yan, Yang, Wu (CR60) 2017; 66 Harrison, Marri, Chalasani (CR105) 2016; 44 Sumida, Yoneda, Hyogo (CR52) 2012; 12 Stiede, Miao, Blanchette (CR106) 2017; 66 Koo, Kim, Joo (CR47) 2017; 66 Rolo, Teodoro, Palmeira (CR31) 2012; 52 Cassinotto, Boursier, de Lédinghen (CR57) 2016; 63 Watanabe, Hashimoto, Ikejima (CR4) 2015; 50 Tokushige, Hashimoto, Kodama (CR17) 2013; 28 BasuRay, Smagris, Cohen, Hobbs (CR37) 2017; 66 Hyogo, Ikegami, Tokushige (CR93) 2011; 41 S BasuRay (1796_CR37) 2017; 66 G Xiao (1796_CR60) 2017; 66 S Chitturi (1796_CR25) 2007; 22 G Musso (1796_CR64) 2012; 55 C Estes (1796_CR3) 2018; 69 SL Friedman (1796_CR101) 2018; 67 Y Sumida (1796_CR108) 2019; 49 P Dongiovanni (1796_CR41) 2015; 61 S Ishibashi (1796_CR104) 2016; 249 Z Younossi (1796_CR22) 2018; 15 S Romeo (1796_CR32) 2008; 40 AJ Sanyal (1796_CR73) 2004; 2 K Stiede (1796_CR106) 2017; 66 MJ Armstrong (1796_CR78) 2016; 387 H Hyogo (1796_CR93) 2011; 41 SM Francque (1796_CR18) 2016; 65 R Safadi (1796_CR103) 2014; 12 X Lv (1796_CR87) 2020; 3 V Ratziu (1796_CR98) 2016; 150 L Castera (1796_CR13) 2019; 156 MC Ryan (1796_CR66) 2013; 59 RM Mancina (1796_CR42) 2016; 05 HS Bajaj (1796_CR84) 2018; 44 S Oh (1796_CR72) 2015; 61 G Vernon (1796_CR27) 2011; 34 K Imajo (1796_CR59) 2016; 150 TG Cotter (1796_CR23) 2020; 158 R Loomba (1796_CR14) 2020; 158 JJ Maher (1796_CR30) 2008; 48 N Houstis (1796_CR29) 2006; 440 Y Sumida (1796_CR52) 2012; 12 J Henao-Mejia (1796_CR46) 2012; 482 DM Torres (1796_CR91) 2011; 54 MJ Armstrong (1796_CR79) 2016; 64 GJ van der Heijden (1796_CR71) 2010; 18 UF Leuschner (1796_CR95) 2010; 52 H Ochi (1796_CR56) 2012; 56 U Summart (1796_CR21) 2017; 6 J Boursier (1796_CR44) 2016; 63 P Dongiovanni (1796_CR89) 2015; 63 R Loomba (1796_CR100) 2018; 67 G Svegliati-Baroni (1796_CR77) 2011; 31 K Kargiotis (1796_CR90) 2015; 21 C Cassinotto (1796_CR57) 2016; 63 Y Kawamura (1796_CR15) 2012; 107 P Angulo (1796_CR10) 2015; 149 M Hamaguchi (1796_CR26) 2012; 18 N Akuta (1796_CR85) 2020; 59 MS Ascha (1796_CR16) 2010; 51 BA Neuschwander-Tetri (1796_CR97) 2015; 385 G Musso (1796_CR76) 2017; 177 M Hashiba (1796_CR7) 2013; 8 T Kawaguchi (1796_CR39) 2018; 13 SA Harrison (1796_CR105) 2016; 44 M Lazo (1796_CR63) 2010; 33 T Kawaguchi (1796_CR34) 2012; 7 R Loomba (1796_CR45) 2017; 25 KD Lindor (1796_CR94) 2004; 39 S He (1796_CR35) 2010; 285 Y Eguchi (1796_CR6) 2012; 47 M Yoneda (1796_CR50) 2011; 46 AP Rolo (1796_CR31) 2012; 52 DH Sinn (1796_CR19) 2016; 151 RJ Wong (1796_CR2) 2015; 148 ZM Younossi (1796_CR1) 2016; 64 K Kodama (1796_CR109) 2013; 36 V Ratziu (1796_CR48) 2005; 128 K Wijarnpreecha (1796_CR68) 2017; 29 S McPherson (1796_CR8) 2015; 62 E Vilar-Gomez (1796_CR65) 2015; 149 AJ Sanyal (1796_CR74) 2010; 362 T Ito (1796_CR51) 2019; 34 AC Sheka (1796_CR24) 2020; 323 P Pingitore (1796_CR36) 2014; 1841 Y Seko (1796_CR38) 2017; 47 BK Koo (1796_CR47) 2017; 66 Y Kawamura (1796_CR53) 2015; 9 S McPherson (1796_CR54) 2017; 112 NA Johnson (1796_CR70) 2009; 50 L Valenti (1796_CR33) 2010; 52 M Yoneda (1796_CR58) 2007; 56 R Sawangjit (1796_CR75) 2016; 95 PS Dulai (1796_CR11) 2017; 65 EASL-EASD-EASO (1796_CR5) 2016; 64 H Ishiba (1796_CR55) 2018; 53 Y Seko (1796_CR83) 2018; 53 J Cui (1796_CR81) 2016; 65 F Bravi (1796_CR69) 2013; 11 S Watanabe (1796_CR4) 2015; 50 N Chalasani (1796_CR9) 2018; 67 E Hashimoto (1796_CR28) 2011; 46 N Akuta (1796_CR88) 2017; 1 M Romero-Gómez (1796_CR67) 2017; 67 J Kozlitina (1796_CR40) 2014; 46 K Promrat (1796_CR62) 2010; 51 K Tokushige (1796_CR17) 2013; 28 G Targher (1796_CR20) 2016; 65 B Donati (1796_CR43) 2017; 7 M Kawakubo (1796_CR82) 2020; 10 GB Goh (1796_CR92) 2015; 35 C Thoma (1796_CR61) 2012; 56 RB Merriman (1796_CR49) 2006; 44 G Musso (1796_CR96) 2010; 52 R Loomba (1796_CR107) 2020; 73 VWS Wong (1796_CR102) 2019; 392 1796_CR12 Y Eguchi (1796_CR80) 2015; 45 CSP Lam (1796_CR86) 2019; 8 ZM Younossi (1796_CR99) 2018; 68 |
| References_xml | – volume: 53 start-page: 140 year: 2018 end-page: 151 ident: CR83 article-title: Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials publication-title: J Gastroenterol doi: 10.1007/s00535-017-1364-8 – volume: 69 start-page: 896 year: 2018 end-page: 904 ident: CR3 article-title: Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.05.036 – volume: 66 start-page: 1111 year: 2017 end-page: 1124 ident: CR37 article-title: The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation publication-title: Hepatology doi: 10.1002/hep.29273 – volume: 7 start-page: e38322 year: 2012 ident: CR34 article-title: Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese publication-title: PLoS ONE doi: 10.1371/journal.pone.0038322 – volume: 68 start-page: 361 year: 2018 end-page: 371 ident: CR99 article-title: Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis publication-title: Hepatology doi: 10.1002/hep.29724 – volume: 49 start-page: 1256 year: 2019 end-page: 1262 ident: CR108 article-title: Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis publication-title: Hepatol Res doi: 10.1111/hepr.13425 – volume: 46 start-page: 352 year: 2014 end-page: 356 ident: CR40 article-title: Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease publication-title: Nat Genet doi: 10.1038/ng.2901 – volume: 61 start-page: 506 year: 2015 end-page: 514 ident: CR41 article-title: Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease publication-title: Hepatology doi: 10.1002/hep.27490 – volume: 39 start-page: 770 year: 2004 end-page: 778 ident: CR94 article-title: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial publication-title: Hepatology doi: 10.1002/hep.20092 – volume: 18 start-page: 1508 year: 2012 end-page: 1516 ident: CR26 article-title: Identification of individuals with non- alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome publication-title: World J Gastroenterol doi: 10.3748/wjg.v18.i13.1508 – volume: 151 start-page: 481 year: 2016 end-page: 488.e1 ident: CR19 article-title: Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.06.001 – volume: 149 start-page: 389 issue: 2 year: 2015 end-page: 97.e10 ident: CR10 article-title: Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease publication-title: Gastroenterology. doi: 10.1053/j.gastro.2015.04.043 – volume: 62 start-page: 1148 year: 2015 end-page: 1155 ident: CR8 article-title: Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management publication-title: J Hepatol doi: 10.1016/j.jhep.2014.11.034 – volume: 67 start-page: 829 year: 2017 end-page: 846 ident: CR67 article-title: Treatment of NAFLD with diet, physical activity and exercise publication-title: J Hepatol doi: 10.1016/j.jhep.2017.05.016 – volume: 3 start-page: e00163 year: 2020 ident: CR87 article-title: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): a systematic review publication-title: Endocrinol Diabetes Metab doi: 10.1002/edm2.163 – volume: 6 start-page: 1630 year: 2017 ident: CR21 article-title: Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: a population-based cross-sectional study publication-title: F1000Res doi: 10.12688/f1000research.12417.1 – volume: 44 start-page: 1183 year: 2016 end-page: 1198 ident: CR105 article-title: Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13816 – volume: 33 start-page: 2156 year: 2010 end-page: 2163 ident: CR63 article-title: Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc10-0856 – volume: 40 start-page: 1461 year: 2008 end-page: 1465 ident: CR32 article-title: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease publication-title: Nat Genet doi: 10.1038/ng.257 – volume: 149 start-page: 367 year: 2015 end-page: 378.e5 ident: CR65 article-title: Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.04.005 – volume: 52 start-page: 1274 year: 2010 end-page: 1280 ident: CR33 article-title: I148M patatin-like phospholipase domain- containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.23823 – volume: 50 start-page: 1105 year: 2009 end-page: 1112 ident: CR70 article-title: Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss publication-title: Hepatology doi: 10.1002/hep.23129 – volume: 48 start-page: 670 year: 2008 end-page: 678 ident: CR30 article-title: Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis publication-title: Hepatology doi: 10.1002/hep.22399 – volume: 22 start-page: 778 year: 2007 end-page: 787 ident: CR25 article-title: Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2007.05001.x – volume: 63 start-page: 1817 year: 2016 end-page: 1827 ident: CR57 article-title: Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy publication-title: Hepatology doi: 10.1002/hep.28394 – volume: 34 start-page: 207 year: 2019 end-page: 214 ident: CR51 article-title: Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.14448 – volume: 35 start-page: 979 year: 2015 end-page: 985 ident: CR92 article-title: Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease publication-title: Liver Int doi: 10.1111/liv.12611 – volume: 15 start-page: 11 year: 2018 end-page: 20 ident: CR22 article-title: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2017.109 – volume: 64 start-page: 73 year: 2016 end-page: 84 ident: CR1 article-title: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology doi: 10.1002/hep.28431 – volume: 44 start-page: 493 year: 2018 end-page: 499 ident: CR84 article-title: SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes publication-title: Diabetes Metab doi: 10.1016/j.diabet.2018.08.001 – volume: 18 start-page: 384 year: 2010 end-page: 390 ident: CR71 article-title: A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents publication-title: Obesity (Silver Spring) doi: 10.1038/oby.2009.274 – volume: 63 start-page: 705 year: 2015 end-page: 712 ident: CR89 article-title: Statin use and non-alcoholic steatohepatitis in at risk individuals publication-title: J Hepatol doi: 10.1016/j.jhep.2015.05.006 – volume: 63 start-page: 764 year: 2016 end-page: 775 ident: CR44 article-title: The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota publication-title: Hepatology doi: 10.1002/hep.28356 – volume: 9 start-page: 269 year: 2015 end-page: 277 ident: CR53 article-title: New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan publication-title: Hepatol Int doi: 10.1007/s12072-014-9605-x – volume: 385 start-page: 956 year: 2015 end-page: 965 ident: CR97 article-title: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(14)61933-4 – volume: 25 start-page: 1054 year: 2017 end-page: 62.e5 ident: CR45 article-title: Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease publication-title: Cell Metab doi: 10.1016/j.cmet.2017.04.001 – volume: 107 start-page: 253 year: 2012 end-page: 261 ident: CR15 article-title: Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma publication-title: Am J Gastroenterol doi: 10.1038/ajg.2011.327 – volume: 7 start-page: 4492 year: 2017 ident: CR43 article-title: MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals publication-title: Sci Rep doi: 10.1038/s41598-017-04991-0 – volume: 12 start-page: 2 year: 2012 ident: CR52 article-title: Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population publication-title: BMC Gastroenterol doi: 10.1186/1471-230X-12-2 – volume: 46 start-page: 1300 year: 2011 end-page: 1306 ident: CR50 article-title: Platelet count for predicting fibrosis in nonalcoholic fatty liver disease publication-title: J Gastroenterol doi: 10.1007/s00535-011-0436-4 – volume: 12 start-page: 2085 year: 2014 end-page: 91.e1 ident: CR103 article-title: The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.04.038 – volume: 36 start-page: 1789 year: 2013 end-page: 1796 ident: CR109 article-title: Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis publication-title: Diabetes Care doi: 10.2337/dc12-1235 – volume: 65 start-page: 589 year: 2016 end-page: 600 ident: CR20 article-title: Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis publication-title: J Hepatol doi: 10.1016/j.jhep.2016.05.013 – volume: 150 start-page: 626 year: 2016 end-page: 37.e7 ident: CR59 article-title: Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.11.048 – volume: 8 start-page: e013389 year: 2019 ident: CR86 article-title: SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects publication-title: J Am Heart Assoc doi: 10.1161/JAHA.119.013389 – volume: 148 start-page: 547 year: 2015 end-page: 555 ident: CR2 article-title: Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.11.039 – volume: 8 start-page: e76161 year: 2013 ident: CR7 article-title: Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease publication-title: PLoS ONE doi: 10.1371/journal.pone.0076161 – volume: 1 start-page: 46 year: 2017 end-page: 52 ident: CR88 article-title: Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies publication-title: Hepatol Commun doi: 10.1002/hep4.1019 – volume: 95 start-page: e4529 year: 2016 ident: CR75 article-title: Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000004529 – volume: 52 start-page: 79 year: 2010 end-page: 104 ident: CR96 article-title: A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.23623 – volume: 10 start-page: 983 year: 2020 ident: CR82 article-title: Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects publication-title: Sci Rep doi: 10.1038/s41598-020-57935-6 – volume: 158 start-page: 1822 year: 2020 end-page: 1830 ident: CR14 article-title: aga clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review publication-title: Gastroenterology doi: 10.1053/j.gastro.2019.12.053 – volume: 112 start-page: 740 year: 2017 end-page: 751 ident: CR54 article-title: Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis publication-title: Am J Gastroenterol doi: 10.1038/ajg.2016.453 – volume: 59 start-page: 1931 year: 2020 end-page: 1937 ident: CR85 article-title: SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology publication-title: Intern Med doi: 10.2169/internalmedicine.4398-19 – volume: 66 start-page: 324 year: 2017 end-page: 334 ident: CR106 article-title: Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study publication-title: Hepatology doi: 10.1002/hep.29246 – volume: 65 start-page: 369 year: 2016 end-page: 376 ident: CR81 article-title: Sitagliptin vs placebo for non-alcoholic fatty liver disease: a randomized controlled trial publication-title: J Hepatol doi: 10.1016/j.jhep.2016.04.021 – volume: 323 start-page: 1175 year: 2020 end-page: 1183 ident: CR24 article-title: Nonalcoholic steatohepatitis: a review publication-title: JAMA doi: 10.1001/jama.2020.2298 – volume: 55 start-page: 885 year: 2012 end-page: 904 ident: CR64 article-title: Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials publication-title: Diabetologia doi: 10.1007/s00125-011-2446-4 – volume: 67 start-page: 328 year: 2018 end-page: 357 ident: CR9 article-title: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases publication-title: Hepatology doi: 10.1002/hep.29367 – volume: 52 start-page: 59 year: 2012 end-page: 69 ident: CR31 article-title: Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2011.10.003 – volume: 387 start-page: 679 year: 2016 end-page: 690 ident: CR78 article-title: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study publication-title: Lancet doi: 10.1016/S0140-6736(15)00803-X – ident: CR12 – volume: 249 start-page: 36 year: 2016 end-page: 43 ident: CR104 article-title: Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2016.02.029 – volume: 45 start-page: 269 year: 2015 end-page: 278 ident: CR80 article-title: Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J) publication-title: Hepatol Res doi: 10.1111/hepr.12351 – volume: 51 start-page: 121 year: 2010 end-page: 129 ident: CR62 article-title: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis publication-title: Hepatology doi: 10.1002/hep.23276 – volume: 2 start-page: 1107 year: 2004 end-page: 1115 ident: CR73 article-title: A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/S1542-3565(04)00457-4 – volume: 41 start-page: 1057 year: 2011 end-page: 1065 ident: CR93 article-title: Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study publication-title: Hepatol Res doi: 10.1111/j.1872-034X.2011.00849.x – volume: 59 start-page: 138 year: 2013 end-page: 143 ident: CR66 article-title: The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2013.02.012 – volume: 31 start-page: 1285 year: 2011 end-page: 1297 ident: CR77 article-title: Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis publication-title: Liver Int doi: 10.1111/j.1478-3231.2011.02462.x – volume: 362 start-page: 1675 year: 2010 end-page: 1685 ident: CR74 article-title: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis publication-title: N Engl J Med doi: 10.1056/NEJMoa0907929 – volume: 156 start-page: 1264 year: 2019 end-page: 1281.e4 ident: CR13 article-title: Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.12.036 – volume: 158 start-page: 1851 year: 2020 end-page: 1864 ident: CR23 article-title: Nonalcoholic fatty liver disease 2020: the state of the disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.01.052 – volume: 440 start-page: 944 year: 2006 end-page: 948 ident: CR29 article-title: Reactive oxygen species have a causal role in multiple forms of insulin resistance publication-title: Nature doi: 10.1038/nature04634 – volume: 64 start-page: 399 year: 2016 end-page: 408 ident: CR79 article-title: Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis publication-title: J Hepatol doi: 10.1016/j.jhep.2015.08.038 – volume: 47 start-page: 586 year: 2012 end-page: 595 ident: CR6 article-title: Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study publication-title: J Gastroenterol doi: 10.1007/s00535-012-0533-z – volume: 56 start-page: 255 year: 2012 end-page: 266 ident: CR61 article-title: Lifestyle interventions for the treatment of non- alcoholic fatty liver disease in adults: a systematic review publication-title: J Hepatol doi: 10.1016/j.jhep.2011.06.010 – volume: 67 start-page: 549 year: 2018 end-page: 559 ident: CR100 article-title: The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial publication-title: Hepatology doi: 10.1002/hep.29514 – volume: 05 start-page: 1219 issue: 150 year: 2016 end-page: 30.e6 ident: CR42 article-title: The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.01.032 – volume: 44 start-page: 874 year: 2006 end-page: 880 ident: CR49 article-title: Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.21346 – volume: 34 start-page: 274 year: 2011 end-page: 285 ident: CR27 article-title: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2011.04724.x – volume: 29 start-page: e8 year: 2017 end-page: e12 ident: CR68 article-title: Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0000000000000776 – volume: 65 start-page: 425 year: 2016 end-page: 443 ident: CR18 article-title: Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications publication-title: J Hepatol doi: 10.1016/j.jhep.2016.04.005 – volume: 128 start-page: 1898 year: 2005 end-page: 1906 ident: CR48 article-title: Sampling variability of liver biopsy in nonalcoholic fatty liver disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2005.03.084 – volume: 65 start-page: 1557 year: 2017 end-page: 1565 ident: CR11 article-title: Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis publication-title: Hepatology doi: 10.1002/hep.29085 – volume: 28 start-page: 88 issue: Suppl 4 year: 2013 end-page: 92 ident: CR17 article-title: Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.12239 – volume: 21 start-page: 7860 year: 2015 end-page: 7868 ident: CR90 article-title: Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome publication-title: World J Gastroenterol doi: 10.3748/wjg.v21.i25.7860 – volume: 73 start-page: 625 issue: 2 year: 2020 end-page: 643 ident: CR107 article-title: Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH publication-title: Hepatology. doi: 10.1002/hep.31622 – volume: 1841 start-page: 574 year: 2014 end-page: 580 ident: CR36 article-title: Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function publication-title: Biochim Biophys Acta doi: 10.1016/j.bbalip.2013.12.006 – volume: 56 start-page: 1271 year: 2012 end-page: 1278 ident: CR56 article-title: Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases publication-title: Hepatology doi: 10.1002/hep.25756 – volume: 47 start-page: 1083 year: 2017 end-page: 1092 ident: CR38 article-title: Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression publication-title: Hepatol Res doi: 10.1111/hepr.12840 – volume: 66 start-page: 1486 year: 2017 end-page: 1501 ident: CR60 article-title: Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis publication-title: Hepatology doi: 10.1002/hep.29302 – volume: 51 start-page: 1972 year: 2010 end-page: 1978 ident: CR16 article-title: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis publication-title: Hepatology doi: 10.1002/hep.23527 – volume: 177 start-page: 633 year: 2017 end-page: 640 ident: CR76 article-title: Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2016.9607 – volume: 54 start-page: 1631 year: 2011 end-page: 1639 ident: CR91 article-title: Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial publication-title: Hepatology doi: 10.1002/hep.24558 – volume: 52 start-page: 472 year: 2010 end-page: 479 ident: CR95 article-title: High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial publication-title: Hepatology doi: 10.1002/hep.23727 – volume: 150 start-page: 1147 year: 2016 end-page: 1159.e5 ident: CR98 article-title: Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.01.038 – volume: 50 start-page: 364 year: 2015 end-page: 377 ident: CR4 article-title: Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis publication-title: J Gastroenterol doi: 10.1007/s00535-015-1050-7 – volume: 66 start-page: 123 year: 2017 end-page: 131 ident: CR47 article-title: Sarcopenia is an independent risk factor for non- alcoholic steatohepatitis and significant fibrosis publication-title: J Hepatol doi: 10.1016/j.jhep.2016.08.019 – volume: 67 start-page: 1754 year: 2018 end-page: 1767 ident: CR101 article-title: A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis publication-title: Hepatology doi: 10.1002/hep.29477 – volume: 392 start-page: 2658 year: 2019 end-page: 2660 ident: CR102 article-title: Fibroblast growth factor 21 for non-alcoholic steatohepatitis publication-title: Lancet doi: 10.1016/S0140-6736(18)32165-2 – volume: 64 start-page: 1388 year: 2016 end-page: 1402 ident: CR5 article-title: Clinical Practice Guidelines for the management of non- alcoholic fatty liver disease publication-title: J Hepatol – volume: 482 start-page: 179 year: 2012 end-page: 185 ident: CR46 article-title: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity publication-title: Nature doi: 10.1038/nature10809 – volume: 53 start-page: 1216 year: 2018 end-page: 1224 ident: CR55 article-title: The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study publication-title: J Gastroenterol doi: 10.1007/s00535-018-1474-y – volume: 285 start-page: 6706 year: 2010 end-page: 6715 ident: CR35 article-title: A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis publication-title: J Biol Chem doi: 10.1074/jbc.M109.064501 – volume: 11 start-page: 1413 year: 2013 end-page: 21.e1 ident: CR69 article-title: Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2013.04.039 – volume: 46 start-page: 63 issue: Suppl 1 year: 2011 end-page: 69 ident: CR28 article-title: Prevalence, gender, ethnic variations, and prognosis of NASH publication-title: J Gastroenterol doi: 10.1007/s00535-010-0311-8 – volume: 61 start-page: 1205 year: 2015 end-page: 1215 ident: CR72 article-title: Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study publication-title: Hepatology doi: 10.1002/hep.27544 – volume: 13 start-page: e0185490 year: 2018 ident: CR39 article-title: Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers publication-title: PLoS ONE doi: 10.1371/journal.pone.0185490 – volume: 56 start-page: 1330 year: 2007 end-page: 1331 ident: CR58 article-title: Transient elastography in patients with non- alcoholic fatty liver disease (NAFLD) publication-title: Gut doi: 10.1136/gut.2007.126417 – volume: 11 start-page: 1413 year: 2013 ident: 1796_CR69 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2013.04.039 – volume: 1 start-page: 46 year: 2017 ident: 1796_CR88 publication-title: Hepatol Commun doi: 10.1002/hep4.1019 – volume: 65 start-page: 369 year: 2016 ident: 1796_CR81 publication-title: J Hepatol doi: 10.1016/j.jhep.2016.04.021 – volume: 150 start-page: 1147 year: 2016 ident: 1796_CR98 publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.01.038 – volume: 158 start-page: 1851 year: 2020 ident: 1796_CR23 publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.01.052 – volume: 29 start-page: e8 year: 2017 ident: 1796_CR68 publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0000000000000776 – volume: 385 start-page: 956 year: 2015 ident: 1796_CR97 publication-title: Lancet doi: 10.1016/S0140-6736(14)61933-4 – volume: 112 start-page: 740 year: 2017 ident: 1796_CR54 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2016.453 – volume: 440 start-page: 944 year: 2006 ident: 1796_CR29 publication-title: Nature doi: 10.1038/nature04634 – volume: 56 start-page: 255 year: 2012 ident: 1796_CR61 publication-title: J Hepatol doi: 10.1016/j.jhep.2011.06.010 – volume: 177 start-page: 633 year: 2017 ident: 1796_CR76 publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2016.9607 – volume: 62 start-page: 1148 year: 2015 ident: 1796_CR8 publication-title: J Hepatol doi: 10.1016/j.jhep.2014.11.034 – volume: 63 start-page: 764 year: 2016 ident: 1796_CR44 publication-title: Hepatology doi: 10.1002/hep.28356 – volume: 49 start-page: 1256 year: 2019 ident: 1796_CR108 publication-title: Hepatol Res doi: 10.1111/hepr.13425 – volume: 50 start-page: 364 year: 2015 ident: 1796_CR4 publication-title: J Gastroenterol doi: 10.1007/s00535-015-1050-7 – volume: 47 start-page: 1083 year: 2017 ident: 1796_CR38 publication-title: Hepatol Res doi: 10.1111/hepr.12840 – volume: 158 start-page: 1822 year: 2020 ident: 1796_CR14 publication-title: Gastroenterology doi: 10.1053/j.gastro.2019.12.053 – volume: 3 start-page: e00163 year: 2020 ident: 1796_CR87 publication-title: Endocrinol Diabetes Metab doi: 10.1002/edm2.163 – volume: 28 start-page: 88 issue: Suppl 4 year: 2013 ident: 1796_CR17 publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.12239 – volume: 18 start-page: 1508 year: 2012 ident: 1796_CR26 publication-title: World J Gastroenterol doi: 10.3748/wjg.v18.i13.1508 – volume: 55 start-page: 885 year: 2012 ident: 1796_CR64 publication-title: Diabetologia doi: 10.1007/s00125-011-2446-4 – volume: 285 start-page: 6706 year: 2010 ident: 1796_CR35 publication-title: J Biol Chem doi: 10.1074/jbc.M109.064501 – volume: 12 start-page: 2 year: 2012 ident: 1796_CR52 publication-title: BMC Gastroenterol doi: 10.1186/1471-230X-12-2 – volume: 61 start-page: 1205 year: 2015 ident: 1796_CR72 publication-title: Hepatology doi: 10.1002/hep.27544 – volume: 66 start-page: 324 year: 2017 ident: 1796_CR106 publication-title: Hepatology doi: 10.1002/hep.29246 – volume: 21 start-page: 7860 year: 2015 ident: 1796_CR90 publication-title: World J Gastroenterol doi: 10.3748/wjg.v21.i25.7860 – volume: 148 start-page: 547 year: 2015 ident: 1796_CR2 publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.11.039 – volume: 392 start-page: 2658 year: 2019 ident: 1796_CR102 publication-title: Lancet doi: 10.1016/S0140-6736(18)32165-2 – volume: 9 start-page: 269 year: 2015 ident: 1796_CR53 publication-title: Hepatol Int doi: 10.1007/s12072-014-9605-x – volume: 56 start-page: 1330 year: 2007 ident: 1796_CR58 publication-title: Gut doi: 10.1136/gut.2007.126417 – volume: 128 start-page: 1898 year: 2005 ident: 1796_CR48 publication-title: Gastroenterology doi: 10.1053/j.gastro.2005.03.084 – volume: 107 start-page: 253 year: 2012 ident: 1796_CR15 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2011.327 – volume: 52 start-page: 1274 year: 2010 ident: 1796_CR33 publication-title: Hepatology doi: 10.1002/hep.23823 – volume: 59 start-page: 138 year: 2013 ident: 1796_CR66 publication-title: J Hepatol doi: 10.1016/j.jhep.2013.02.012 – volume: 64 start-page: 1388 year: 2016 ident: 1796_CR5 publication-title: J Hepatol – volume: 31 start-page: 1285 year: 2011 ident: 1796_CR77 publication-title: Liver Int doi: 10.1111/j.1478-3231.2011.02462.x – volume: 482 start-page: 179 year: 2012 ident: 1796_CR46 publication-title: Nature doi: 10.1038/nature10809 – volume: 52 start-page: 79 year: 2010 ident: 1796_CR96 publication-title: Hepatology doi: 10.1002/hep.23623 – volume: 387 start-page: 679 year: 2016 ident: 1796_CR78 publication-title: Lancet doi: 10.1016/S0140-6736(15)00803-X – volume: 149 start-page: 389 issue: 2 year: 2015 ident: 1796_CR10 publication-title: Gastroenterology. doi: 10.1053/j.gastro.2015.04.043 – volume: 61 start-page: 506 year: 2015 ident: 1796_CR41 publication-title: Hepatology doi: 10.1002/hep.27490 – volume: 67 start-page: 829 year: 2017 ident: 1796_CR67 publication-title: J Hepatol doi: 10.1016/j.jhep.2017.05.016 – volume: 18 start-page: 384 year: 2010 ident: 1796_CR71 publication-title: Obesity (Silver Spring) doi: 10.1038/oby.2009.274 – volume: 8 start-page: e013389 year: 2019 ident: 1796_CR86 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.119.013389 – volume: 2 start-page: 1107 year: 2004 ident: 1796_CR73 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/S1542-3565(04)00457-4 – volume: 35 start-page: 979 year: 2015 ident: 1796_CR92 publication-title: Liver Int doi: 10.1111/liv.12611 – volume: 65 start-page: 1557 year: 2017 ident: 1796_CR11 publication-title: Hepatology doi: 10.1002/hep.29085 – volume: 64 start-page: 73 year: 2016 ident: 1796_CR1 publication-title: Hepatology doi: 10.1002/hep.28431 – volume: 66 start-page: 123 year: 2017 ident: 1796_CR47 publication-title: J Hepatol doi: 10.1016/j.jhep.2016.08.019 – volume: 53 start-page: 140 year: 2018 ident: 1796_CR83 publication-title: J Gastroenterol doi: 10.1007/s00535-017-1364-8 – volume: 46 start-page: 1300 year: 2011 ident: 1796_CR50 publication-title: J Gastroenterol doi: 10.1007/s00535-011-0436-4 – volume: 53 start-page: 1216 year: 2018 ident: 1796_CR55 publication-title: J Gastroenterol doi: 10.1007/s00535-018-1474-y – volume: 50 start-page: 1105 year: 2009 ident: 1796_CR70 publication-title: Hepatology doi: 10.1002/hep.23129 – volume: 44 start-page: 1183 year: 2016 ident: 1796_CR105 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13816 – volume: 13 start-page: e0185490 year: 2018 ident: 1796_CR39 publication-title: PLoS ONE doi: 10.1371/journal.pone.0185490 – volume: 46 start-page: 352 year: 2014 ident: 1796_CR40 publication-title: Nat Genet doi: 10.1038/ng.2901 – volume: 73 start-page: 625 issue: 2 year: 2020 ident: 1796_CR107 publication-title: Hepatology. doi: 10.1002/hep.31622 – volume: 1841 start-page: 574 year: 2014 ident: 1796_CR36 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbalip.2013.12.006 – volume: 65 start-page: 425 year: 2016 ident: 1796_CR18 publication-title: J Hepatol doi: 10.1016/j.jhep.2016.04.005 – volume: 33 start-page: 2156 year: 2010 ident: 1796_CR63 publication-title: Diabetes Care doi: 10.2337/dc10-0856 – volume: 249 start-page: 36 year: 2016 ident: 1796_CR104 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2016.02.029 – volume: 151 start-page: 481 year: 2016 ident: 1796_CR19 publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.06.001 – volume: 36 start-page: 1789 year: 2013 ident: 1796_CR109 publication-title: Diabetes Care doi: 10.2337/dc12-1235 – volume: 34 start-page: 274 year: 2011 ident: 1796_CR27 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2011.04724.x – volume: 67 start-page: 1754 year: 2018 ident: 1796_CR101 publication-title: Hepatology doi: 10.1002/hep.29477 – volume: 150 start-page: 626 year: 2016 ident: 1796_CR59 publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.11.048 – volume: 51 start-page: 121 year: 2010 ident: 1796_CR62 publication-title: Hepatology doi: 10.1002/hep.23276 – volume: 45 start-page: 269 year: 2015 ident: 1796_CR80 publication-title: Hepatol Res doi: 10.1111/hepr.12351 – volume: 362 start-page: 1675 year: 2010 ident: 1796_CR74 publication-title: N Engl J Med doi: 10.1056/NEJMoa0907929 – volume: 52 start-page: 59 year: 2012 ident: 1796_CR31 publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2011.10.003 – volume: 12 start-page: 2085 year: 2014 ident: 1796_CR103 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.04.038 – volume: 51 start-page: 1972 year: 2010 ident: 1796_CR16 publication-title: Hepatology doi: 10.1002/hep.23527 – volume: 59 start-page: 1931 year: 2020 ident: 1796_CR85 publication-title: Intern Med doi: 10.2169/internalmedicine.4398-19 – volume: 68 start-page: 361 year: 2018 ident: 1796_CR99 publication-title: Hepatology doi: 10.1002/hep.29724 – volume: 66 start-page: 1486 year: 2017 ident: 1796_CR60 publication-title: Hepatology doi: 10.1002/hep.29302 – volume: 25 start-page: 1054 year: 2017 ident: 1796_CR45 publication-title: Cell Metab doi: 10.1016/j.cmet.2017.04.001 – volume: 95 start-page: e4529 year: 2016 ident: 1796_CR75 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000004529 – volume: 69 start-page: 896 year: 2018 ident: 1796_CR3 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.05.036 – volume: 63 start-page: 1817 year: 2016 ident: 1796_CR57 publication-title: Hepatology doi: 10.1002/hep.28394 – volume: 56 start-page: 1271 year: 2012 ident: 1796_CR56 publication-title: Hepatology doi: 10.1002/hep.25756 – volume: 39 start-page: 770 year: 2004 ident: 1796_CR94 publication-title: Hepatology doi: 10.1002/hep.20092 – volume: 6 start-page: 1630 year: 2017 ident: 1796_CR21 publication-title: F1000Res doi: 10.12688/f1000research.12417.1 – volume: 40 start-page: 1461 year: 2008 ident: 1796_CR32 publication-title: Nat Genet doi: 10.1038/ng.257 – volume: 48 start-page: 670 year: 2008 ident: 1796_CR30 publication-title: Hepatology doi: 10.1002/hep.22399 – volume: 46 start-page: 63 issue: Suppl 1 year: 2011 ident: 1796_CR28 publication-title: J Gastroenterol doi: 10.1007/s00535-010-0311-8 – volume: 44 start-page: 493 year: 2018 ident: 1796_CR84 publication-title: Diabetes Metab doi: 10.1016/j.diabet.2018.08.001 – volume: 44 start-page: 874 year: 2006 ident: 1796_CR49 publication-title: Hepatology doi: 10.1002/hep.21346 – volume: 149 start-page: 367 year: 2015 ident: 1796_CR65 publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.04.005 – volume: 63 start-page: 705 year: 2015 ident: 1796_CR89 publication-title: J Hepatol doi: 10.1016/j.jhep.2015.05.006 – volume: 7 start-page: e38322 year: 2012 ident: 1796_CR34 publication-title: PLoS ONE doi: 10.1371/journal.pone.0038322 – volume: 47 start-page: 586 year: 2012 ident: 1796_CR6 publication-title: J Gastroenterol doi: 10.1007/s00535-012-0533-z – volume: 67 start-page: 328 year: 2018 ident: 1796_CR9 publication-title: Hepatology doi: 10.1002/hep.29367 – volume: 156 start-page: 1264 year: 2019 ident: 1796_CR13 publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.12.036 – volume: 54 start-page: 1631 year: 2011 ident: 1796_CR91 publication-title: Hepatology doi: 10.1002/hep.24558 – volume: 41 start-page: 1057 year: 2011 ident: 1796_CR93 publication-title: Hepatol Res doi: 10.1111/j.1872-034X.2011.00849.x – volume: 8 start-page: e76161 year: 2013 ident: 1796_CR7 publication-title: PLoS ONE doi: 10.1371/journal.pone.0076161 – volume: 05 start-page: 1219 issue: 150 year: 2016 ident: 1796_CR42 publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.01.032 – volume: 15 start-page: 11 year: 2018 ident: 1796_CR22 publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2017.109 – volume: 65 start-page: 589 year: 2016 ident: 1796_CR20 publication-title: J Hepatol doi: 10.1016/j.jhep.2016.05.013 – volume: 52 start-page: 472 year: 2010 ident: 1796_CR95 publication-title: Hepatology doi: 10.1002/hep.23727 – volume: 64 start-page: 399 year: 2016 ident: 1796_CR79 publication-title: J Hepatol doi: 10.1016/j.jhep.2015.08.038 – volume: 7 start-page: 4492 year: 2017 ident: 1796_CR43 publication-title: Sci Rep doi: 10.1038/s41598-017-04991-0 – volume: 67 start-page: 549 year: 2018 ident: 1796_CR100 publication-title: Hepatology doi: 10.1002/hep.29514 – volume: 34 start-page: 207 year: 2019 ident: 1796_CR51 publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.14448 – ident: 1796_CR12 doi: 10.1111/jgh.14989 – volume: 323 start-page: 1175 year: 2020 ident: 1796_CR24 publication-title: JAMA doi: 10.1001/jama.2020.2298 – volume: 66 start-page: 1111 year: 2017 ident: 1796_CR37 publication-title: Hepatology doi: 10.1002/hep.29273 – volume: 10 start-page: 983 year: 2020 ident: 1796_CR82 publication-title: Sci Rep doi: 10.1038/s41598-020-57935-6 – volume: 22 start-page: 778 year: 2007 ident: 1796_CR25 publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2007.05001.x |
| SSID | ssj0013058 |
| Score | 2.6792085 |
| SecondaryResourceType | review_article |
| Snippet | Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 951 |
| SubjectTerms | Abdominal Surgery Balloon treatment Biopsy Cardiac patients Cardiovascular diseases Cirrhosis Clinical medicine Clinical practice guidelines Clinical trials Colorectal Surgery Disease Progression Drug therapy Etiology Evidence-based medicine Evidence-Based Practice - methods Evidence-Based Practice - trends Fatty liver Fibrosis Gastroenterology Glucagon Glucagon-like peptide 1 Glucose transporter Guidelines as Topic Health aspects Hepatocellular carcinoma Hepatology Humans Japan Liver Liver cancer Liver cirrhosis Liver diseases Medical screening Medicine Medicine & Public Health Non-alcoholic Fatty Liver Disease - diagnosis Non-alcoholic Fatty Liver Disease - physiopathology Non-alcoholic Fatty Liver Disease - therapy Patients Practice guidelines (Medicine) Prognosis Public health Review Review Article Surgical Oncology Vitamin E |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BFiEkxKO8QgsyEhIHsJp1sk5yqlrUigOsKgRSb5bt2G2larfsZlH598w4TrZZiV44206c-PP4G88L4D1CIJdmYnlqHCoolbRcl67gVVlnQmuJnCIkcf1aTKfl6Wl1Ei_cltGtspOJQVDXc0t35HsCT0rUnMos3b_6xalqFFlXYwmNu7BFmcryEWwdHk1Pvq_tCGmo0Ik6TM7HSL5j2EwIngupTTi5KBAqJb8eHE2bAvrGCbXpPblhQg0n0_Hj__2mJ_AoclJ20ILoKdxxs224_y1a3bfhYXu3x9qQpWew6EqRcjoDa9ZFV7Iu5IqdrSh7FnnUMyTFbEZ0P5Tixad43TR_2CX5g7BoHtobdCDcNfNzR77ezcWSCeSaz-Hn8dGPz194rN3ALVLEhossN5lxvnSlnwhflKlwqNk4lK2ocUlhZI3kSLgQqSuQl2TC-KqurLFiorMiewEjfLd7BcyT5VR6Pcm0IfVTa288ykWXo26ra5nAuFs2ZWNic6qvcan6lMxhqRUutQpLra4T-NiPuWrTetza-wOhQdGexydbHUMXcH6UPUsdFONgfkzTBHYHPXGv2mFzBwQVZcVSrVGQwLu-mUaS_9vMzVfUhxRH8mFK4GULv37eWY6UHf9lAsUAmH0HyiA-bJldnIdM4sjVxqnEkZ86CK-n9e_f8fr2r9iBB4J2VQjY3IVRs1i5N3DP_kbILN7GHfoXGYZBGA priority: 102 providerName: ProQuest |
| Title | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 |
| URI | https://link.springer.com/article/10.1007/s00535-021-01796-x https://www.ncbi.nlm.nih.gov/pubmed/34533632 https://www.proquest.com/docview/2584132830 https://www.proquest.com/docview/2574390423 https://pubmed.ncbi.nlm.nih.gov/PMC8531062 |
| Volume | 56 |
| WOSCitedRecordID | wos000696755500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1435-5922 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013058 issn: 0944-1174 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_BhhAvfH8ExmQkJB7AWmqnifM40CYeWDUVmPpm2Y7NKk0dalME_z13rpORCpDgxVLlc-pczuff6b4AXqIIFKUdO55bjwZKXTpulK94rRopjCkRU8Qirh-qyUTNZvVpSgpbddHunUsyauo-2S2WIuEUUkBSVHJEjrt43Sk6jtOPZ1e-gzx25US7peAjBNwpVeb3zxhcR9tK-ZdbaTticsttGm-j4zv_9x534XZCn-xwIy734Jpf3IebJ8m__gCWXZNRTrdbw7q8SdYlU7Eva6qLRbHyDOEuWxCQj012544F07Y_2AVFerDk-DkYEJBEtZfnnqK42_mKCUSRD-Hz8dGnd-956srAHYK_lgtZWGl9UF6FsQiVyoVHm8Wj1kRbqhS2bBD2CB9zcAUiDilsqJvaWSfGRlbyEezgf_snwAL5RMtgxtJYMiyNCTagxvMFWq2mKTMYdR9Hu1SynDpnXOi-2HJkpkZm6shM_T2D1_2ar5uCHX-lfkXfXNNpxic7k5IScH9UF0sfVqPoWMzzDPYGlHgK3XC6kxqdtMBKC0R3-PpK4vSLfppWUmTbwl-uiYZMQopOyuDxRsj6fcsCwTjyMoNqIH49AdUGH84s5uexRjiiMDT2ceWbTgivtvVndjz9N_JncEuQHMfUzD3YaZdr_xxuuG8oQst9uF5Nz2icVXFU-7D79mhyOsVfJzmNeGp_Aua7NwM |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qBQESYilboICRQBzAauJkshwQqoCqVacjhArqzdiOTStVM2UmA-2f4jfynrMMGYneeuDsJY7zvS1vA3iBEEhSPTA81BYNlCI1XOU240VexkKpFHUKX8R1mI1G-cFB8WkFfre5MBRW2fJEz6jLiaF_5BsCJSVaTnkcvjv5walrFHlX2xYaNSx27dkvNNlmb3c-4Pd9KcTWx_3327zpKsANKi8VF3GiY21dbnM3EC7LQ2FR57ZI9WgLpEKnJYptYX0OqUCJGQvtirIw2oiBirMY970El5GPRxRCln3-uvBahL4fKFpMCY9Q1W-SdHyqni-kwikggmgg5ac9QbgsDv6Sh8uxmksOWy8Ht279bzd4G242GjfbrEnkDqzY8Rpc3WtiCtbgRv3nktUJWXdh2jZa5SThS9bmjrI2oYx9n1NtMMoXYKjyszEZM77RMO7iVFWdsWOKdmGN82ujN4GoqpocWopkr45mTKAmfQ--XMgN3IdVfLZ9CMyRXzh1ahArTca1Uk475Po2QctdlWkAUQsTaZqy7dQ95Fh2Bac9tCRCS3poydMAXndrTuqiJefOfkXok8TRcGejmsQMPB_VBpObWeSdq2EYwHpvJnIi0x9ugScbTjiTC9QF8LwbppUU3Te2kznNIbOYIrQCeFDDvTt3nKBBgncZQNYjhG4C1Ufvj4yPDn2ddNREozDFlW9aklkc69_X8ej8t3gG17b394ZyuDPafQzXBVG0T01dh9VqOrdP4Ir5ifCZPvW8gcG3iyalPzbPmdI |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qBVVIiKUUSClgJBAHak3GyWQ5IFRRRlQtowqB1JuxHZtWqmbKTIa2f41fx3vOMmQkeuuBs5c4zve2vA3gFUIgTvTA8FBbNFDyxHCV2ZTnWREJpRLUKXwR14N0NMqOjvLDFfjd5MJQWGXDEz2jLiaG_pH3BEpKtJyyKOy5OizicHf4_uwnpw5S5Glt2mlUENm3l-dovs3e7e3it34txPDj1w-feN1hgBtUZEouolhH2rrMZm4gXJqFwqL-bZEDoF2QCJ0UKMKF9fmkAqVnJLTLi9xoIwYqSiPc9wbcTMk5SGGD4ZeFByP0vUHReop5H9X-OmHHp-35oiqcgiOIHhJ-0RGKy6LhL9m4HLe55Lz1MnF473--zftwt9bE2U5FOg9gxY7XYe1zHWuwDneqP5qsStR6CNOmASsnyV-wJqeUNYlm7MecaoZRHgFDU4CNycjxDYhxF6fK8pKdUhQMq51ivc4EorZycmwpwr08mTGBGvYGfLuWG3gEq_hs-wSYI39x4tQgUpqMbqWcdigNbIwWvSqSAPoNZKSpy7lTV5FT2Rai9jCTCDPpYSYvAnjbrjmriplcOfsNIVESp8OdjaoTNvB8VDNM7qR973QNwwC2OjORQ5nucANCWXPImVwgMICX7TCtpKi_sZ3MaQ6ZyxS5FcDjCvrtuaMYDRW8ywDSDlG0E6huendkfHLs66ejhtoPE1y53ZDP4lj_vo7Nq9_iBawhBcmDvdH-U7gtiLh9xuoWrJbTuX0Gt8wvRM_0uWcTDL5fNyX9AauVom8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evidence-based+clinical+practice+guidelines+for+nonalcoholic+fatty+liver+disease%2Fnonalcoholic+steatohepatitis+2020&rft.jtitle=Journal+of+gastroenterology&rft.au=Tokushige%2C+Katsutoshi&rft.au=Ikejima%2C+Kenichi&rft.au=Ono%2C+Masafumi&rft.au=Eguchi%2C+Yuichiro&rft.date=2021-11-01&rft.issn=1435-5922&rft.eissn=1435-5922&rft.volume=56&rft.issue=11&rft.spage=951&rft_id=info:doi/10.1007%2Fs00535-021-01796-x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0944-1174&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0944-1174&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0944-1174&client=summon |